Welcome to our dedicated page for NLTX news (Ticker: NLTX), a resource for investors and traders seeking the latest updates and insights on NLTX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NLTX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NLTX's position in the market.
Neoleukin Therapeutics (NASDAQ:NLTX) announced that CEO Jonathan Drachman will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. A pre-recorded presentation will be available on-demand starting March 9, 2021, at 7:00 am ET via the Neoleukin investors section of their website. Neoleukin specializes in de novo protein therapeutics, focusing on advanced immunotherapies for cancer and autoimmune diseases. Their lead candidate is NL-201, an agonist designed to enhance tolerability and efficacy.
Neoleukin Therapeutics, a biopharmaceutical company listed on NASDAQ under the ticker NLTX, announced that CEO Jonathan Drachman will participate in a fireside chat at the Guggenheim Healthcare Talks | 2021 Oncology Days on March 12, 2021, at 3 p.m. ET. A live audio webcast will be available on the company's investor website, along with an archived replay for 30 days post-event. Neoleukin focuses on creating next-generation immunotherapies using de novo protein design technology, with its lead candidate, NL-201, targeting improved efficacy and tolerability.
Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) announced on January 7, 2021, that it received a clinical hold letter from the FDA regarding its IND application for the Phase 1 study of NL-201, its immunotherapeutic candidate. The FDA's hold requires Neoleukin to develop a new assay for accurately measuring protein dosage and address additional non-hold related requests. CEO Jonathan Drachman expressed the company's commitment to respond swiftly and work closely with the FDA to resolve these issues.
NL-201 is designed to enhance cancer-fighting CD8 T cells and NK cells.
Neoleukin Therapeutics (NASDAQ:NLTX) announced that CEO Jonathan Drachman will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on January 14, 2021, at 4:30 p.m. ET. The presentation will include a live audio webcast and a subsequent Q&A session, accessible via the Neoleukin investor website. Neoleukin focuses on developing next-generation immunotherapies using de novo protein design technology, with its leading candidate, NL-201, aimed at enhancing the treatment of cancer and autoimmune diseases.
Neoleukin Therapeutics (NASDAQ:NLTX) has submitted an Investigational New Drug (IND) Application to the U.S. FDA for its lead immunotherapeutic candidate, NL-201, marking a significant milestone for the company. NL-201 is designed to mimic natural cytokines IL-2 and IL-15. The Phase 1 clinical trial, which will include up to 120 patients with relapsed or refractory solid tumors, aims to evaluate safety and anti-tumor activity. The study will be conducted in North America and Australia, with patient enrollment expected to commence soon.
Neoleukin Therapeutics (NASDAQ:NLTX) announced that CEO Jonathan Drachman will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. The pre-recorded session will be available starting at 10 a.m. ET on November 23, 2020, via the investors section of Neoleukin's website. Neoleukin focuses on developing next-generation immunotherapies, leveraging innovative computational methods for protein design. Their lead candidate, NL-201, combines IL-2 and IL-15 agonists aimed at enhancing therapeutic benefits.
Neoleukin Therapeutics (NASDAQ:NLTX) announced that CEO Jonathan Drachman will present at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 4:40 p.m. ET. The event will be available via live audio webcast on the Neoleukin website, with an archived replay accessible for 30 days post-event. Neoleukin specializes in developing immunotherapies for cancer and autoimmune diseases using advanced computational methods to design innovative protein therapeutics. Their lead candidate, NL-201, aims to enhance efficacy by targeting specific receptors.
Summary not available.
Neoleukin Therapeutics (NASDAQ: NLTX) reported financial results for Q3 2020, ending with $201.2 million in cash, up from $143.1 million at the end of 2019. The company is on track to submit an IND for NL-201, its lead immunotherapy candidate, by year-end 2020, and has submitted a CTN application in Australia. R&D expenses rose to $6.2 million, reflecting ongoing development, while general and administrative expenses decreased to $3.9 million. A gain of $7.8 million from the sale of Aquinox Canada contributed to a reduced net loss of $2.2 million, down from $59.1 million the prior year.
Neoleukin Therapeutics (NASDAQ:NLTX) announced a significant breakthrough in COVID-19 treatment with their de novo protein, NL-CVX1. Published in Science, the research demonstrates that NL-CVX1 effectively prevents SARS-CoV-2 infection in hamsters, maintaining survival after exposure to a lethal virus dose. This protein mimics the natural receptor for SARS-CoV-2, showing promise against viral mutations. The company is evaluating advancing this promising molecule to clinical trials in humans, showcasing their innovative protein design technology.
